机构:[1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, 10 Tie Yi Rd, Beijing 100038, Peoples R China[2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Nephrol, 10 Tie Yi Rd, Beijing 100053, Peoples R China首都医科大学宣武医院[3]Key Lab Canc FSMP State Market Regulat, 10 Tie Yi Rd, Beijing 100038, Peoples R China[4]Capital Med Univ, Lab Clin Med, Clin Lab Med, 10 Tie Yi Rd, Beijing 100038, Peoples R China[5]Sichuan Univ, West China Hosp, Clin Nutr Dept, Chengdu 610041, Sichuan, Peoples R China四川大学华西医院[6]Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Dept Pathol, Natl Canc Ctr, Beijing 100038, Peoples R China[7]Guangxi Med Univ, Sch Preclin Med, Dept Parasitol, Nanning 530021, Peoples R China[8]Yunnan Univ, Kunming 650091, Yunnan, Peoples R China[9]Gen Surg Clin Med Ctr Yunnan Prov, Kunming 650032, Yunnan, Peoples R China
BackgroundThe C-reactive protein (CRP)-triglyceride-glucose (TyG) index (CTI), which is a measure representing the level of inflammation and insulin resistance (IR), is related to poor cancer prognosis; however, the CTI has not been validated in patients with cancer cachexia. Thus, this study aimed to explore the potential clinical value of the CTI in patients with cancer cachexia.MethodsIn this study, our prospective multicenter cohort included 1411 patients with cancer cachexia (mean age 59.45 +/- 11.38, 63.3% male), which was a combined analysis of multiple cancer types. We randomly selected 30% of the patients for the internal test cohort (mean age 58.90 +/- 11.22% 61.4% male). Additionally, we included 307 patients with cancer cachexia in the external validation cohort (mean age 61.16 +/- 11, 58.5% male). Receiver operating characteristic (ROC) and calibration curves were performed to investigate the prognostic value of CTI. The prognostic value of the CTI was also investigated performing univariate and multivariate survival analyses.ResultsThe survival curve indicated that the CTI showed a significant prognostic value in the total, internal, and external validation cohorts. Prognostic ROC curves and calibration curves revealed that the CTI showed good consistency in predicting the survival of patients with cancer cachexia. Multivariate survival analysis showed that an elevated CTI increased the risk of death by 22% (total cohort, 95% confidence interval [CI] = 1.13-1.33), 34% (internal test cohort, 95%CI = 1.11-1.62), and 35% (external validation cohort, 95%CI = 1.14-1.59) for each increase in the standard deviation of CTI. High CTI reliably predicted shorter survival (total cohort, hazard ratio [HR] = 1.45, 95%CI = 1.22-1.71; internal test cohort, HR = 1.62, 95%CI = 1.12-2.36; external validation cohort, HR = 1.61, 95%CI = 1.15-2.26). High CTI significantly predicted shorter survival in different tumor subgroups, such as esophageal [HR = 2.11, 95%CI = 1.05-4.21] and colorectal cancer [HR = 2.29, 95%CI = 1.42-3.71]. The mediating effects analysis found that the mediating proportions of PGSGA, ECOG PS, and EORTC QLQ-C30 on the direct effects of CTI were 21.72%, 19.63%, and 11.61%, respectively We found that there was a significant positive correlation between the CTI and 90-day [HR = 2.48, 95%CI = 1.52-4.14] and 180-day mortality [HR = 1.77,95%CI = 1.24-2.55] in patients with cancer cachexia.ConclusionThe CTI can predict the short- and long-term survival of patients with cancer cachexia and provide a useful prognostic tool for clinical practice.
基金:
This work was supported by the National Key Research and Development
Program [grant number 2017YFC1309200] and [2022YFC2009600]) and
the Beijing Municipal Science and Technology Commission [grant number
SCW2018-06].
第一作者机构:[1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, 10 Tie Yi Rd, Beijing 100038, Peoples R China[2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Nephrol, 10 Tie Yi Rd, Beijing 100053, Peoples R China[3]Key Lab Canc FSMP State Market Regulat, 10 Tie Yi Rd, Beijing 100038, Peoples R China[4]Capital Med Univ, Lab Clin Med, Clin Lab Med, 10 Tie Yi Rd, Beijing 100038, Peoples R China
共同第一作者:
通讯作者:
通讯机构:[1]Capital Med Univ, Beijing Shijitan Hosp, Dept Gastrointestinal Surg, Dept Clin Nutr, 10 Tie Yi Rd, Beijing 100038, Peoples R China[2]Capital Med Univ, Xuanwu Hosp, Natl Clin Res Ctr Geriatr Dis, Dept Nephrol, 10 Tie Yi Rd, Beijing 100053, Peoples R China[3]Key Lab Canc FSMP State Market Regulat, 10 Tie Yi Rd, Beijing 100038, Peoples R China[4]Capital Med Univ, Lab Clin Med, Clin Lab Med, 10 Tie Yi Rd, Beijing 100038, Peoples R China
推荐引用方式(GB/T 7714):
Ruan Guo-Tian,Deng Li,Xie Hai-Lun,et al.Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia[J].CANCER & METABOLISM.2024,12(1):doi:10.1186/s40170-024-00332-8.
APA:
Ruan, Guo-Tian,Deng, Li,Xie, Hai-Lun,Shi, Jin-Yu,Liu, Xiao-Yue...&Shi, Han-Ping.(2024).Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia.CANCER & METABOLISM,12,(1)
MLA:
Ruan, Guo-Tian,et al."Systemic inflammation and insulin resistance-related indicator predicts poor outcome in patients with cancer cachexia".CANCER & METABOLISM 12..1(2024)